EP3533447
Fljótandi samsetningar af bendamústín til notkunar í aðferð til meðhöndlunar á kvillum sem sýna svörun við bendamústín í sjúklingum sem þarfnast minnkaðs rúmmáls til gjafar
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
15.3.2013EP published:
15.3.2023EP application number:
19151152.6
EP translation filed:
24.4.2023Grant published:
15.5.2023EPO information:
European Patent Register
Max expiry date:
14.3.2033Expiry date:
14.3.2027Next due date:
31.3.2027
Title in English:
BENDAMUSTINE LIQUID COMPOSITIONS FOR USE IN METHOD OF TREATING BENDAMUSTINE-RESPONSIVE CONDITIONS IN PATIENTS REQUIRING REDUCED VOLUMES FOR ADMINISTRATIONLanguage of the patent:
English
Timeline
Today
15.3.2013EP application
15.3.2023EP Publication
24.4.2023Translation submitted
15.5.2023Registration published
14.3.2027Expires
Owner
Name:
Eagle Pharmaceuticals, Inc.Address:
50 Tice Boulevard Suite 315, Woodcliff Lake, NJ 07677, US
Inventor
Name:
SUNDARAM, SrikanthAddress:
Somerset, NJ 08873, US
Name:
TARRIFF, Scott, L.Address:
Mahwah, NJ 07430, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201261613173 PDate:
20.3.2012Country:
US
Number:
201261669889 PDate:
10.7.2012Country:
US
Number:
201261678715 PDate:
2.8.2012Country:
US
Classification
Categories:
A61K 31/4184, A61K 47/10, A61K 9/00, A61K 47/02, A61K 47/20
Annual fees
Number
Paid
Expires
Payer
Number: 11
Paid: 19.4.2023
Expires: 14.3.2024
Payer: Árnason Faktor ehf.
Number: 12
Paid: 28.2.2024
Expires: 14.3.2025
Payer: Árnason Faktor ehf.
Number: 13
Paid: 11.2.2025
Expires: 14.3.2026
Payer: Árnason Faktor ehf.
Number: 14
Paid: 12.3.2026
Expires: 14.3.2027
Payer: Árnason Faktor ehf.